Page last updated: 2024-12-05

setiptiline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Setiptiline is a tetracyclic antidepressant that was marketed in Europe for the treatment of depression. It is a potent inhibitor of serotonin reuptake and has also been shown to have some affinity for the norepinephrine transporter. Setiptiline was withdrawn from the market in several countries due to concerns about its safety, including reports of hepatotoxicity. However, it continues to be studied as a potential treatment for depression and other conditions, such as anxiety and obsessive-compulsive disorder. Research on setiptiline focuses on its pharmacological properties, its therapeutic potential, and its safety profile. It is studied to understand its mechanism of action, its effectiveness in treating various mental health conditions, and to identify potential risks associated with its use.'

setiptiline: structure given in UD 37:228j [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

setiptiline : A tetracyclic antidepressant that is 2,3,4,9-tetrahydro-1H-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine carrying a methyl group at position 2. Its maleate salt is used for the treatment of depression in Japan. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5205
CHEMBL ID2104895
CHEBI ID135076
SCHEMBL ID211362
MeSH IDM0144408

Synonyms (45)

Synonym
org-8282
setiptiline [inn]
2,3,4,9-tetrahydro-2-methyl-1h-dibenzo(3,4:6,7)cyclohepta(1,2-c)pyridine
brn 1650422
org 8282
mo 8282
setiptiline
setiptilina [spanish]
1h-dibenzo(3,4:6,7)cyclohepta(1,2-c)pyridine, 2,3,4,9-tetrahydro-2-methyl-
einecs 260-653-4
setiptilinum [latin]
CHEBI:135076
L003337
setiptiline (inn)
57262-94-9
D08511
setiptilina
unii-7l38105z6e
7l38105z6e ,
setiptilinum
CHEMBL2104895
HY-32329
CS-1181
FT-0674569
2,3,4,9-tetrahydro-2-methyl-1h-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine
SCHEMBL211362
setiptiline [who-dd]
setiptiline [mart.]
setiptiline [mi]
GVPIXRLYKVFFMK-UHFFFAOYSA-N
1h-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine, 2,3,4,9-tetrahydro-2-methyl-
1,2,3,4-tetrahydro-2-methyl-1h-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine
tecipul [as maleate]
DTXSID50205886
DB09304
AKOS030526164
NCGC00378937-02
4-methyl-4-azatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),2(7),8,10,12,15,17-heptaene
Q6590424
2-methyl-2,3,4,9-tetrahydro-1h-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine
NCGC00378937-01
F84903
MS-23683
4-methyl-4-azatetracyclo[13.4.0.0^{2,7.0^{8,13]nonadeca-1(19),2(7),8,10,12,15,17-heptaene
A923887

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tetracyclic antidepressantAn antidepressant whose molecular structure consists of four ring-like structures in a T-shape.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6Homo sapiens (human)Potency0.47720.00108.379861.1304AID1645840
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (14.29)18.7374
1990's8 (57.14)18.2507
2000's1 (7.14)29.6817
2010's1 (7.14)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.97 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.67%)5.53%
Reviews1 (6.67%)6.00%
Case Studies2 (13.33%)4.05%
Observational0 (0.00%)0.25%
Other11 (73.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]